Leerink Partners on WAVE Life Sciences (WVE) after obesity data disappoints: selloff 'very overdone'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Leerink Partners on WAVE Life Sciences (WVE) after obesity data disappoints: selloff 'very overdone'
March 27, 2026 5:04 AM EDT
RBC Capital analyst Luca Issi reiterated an Outperform rating and $27.00 price target on WAVE Life Sciences (NASDAQ: WVE).
The analyst comments "The news: WVE reported updated INHBE data. At 240 mg, company reported 0.3/0.9% reductions in body weight (at 3/6 months), 8/14% reductions in visceral fats, 5/5% reduction in total fat and 2/2% increase in lean mass. At 400 mg, weight loss data at 3 months was not shared (we assume negligible), but WVE notes 5% reduction in visceral fats and 0.7% reduction in total fats. On lack of weight loss, WVE notes that the patients enrolled have materially... More
March 26, 2026 4:21 PM EDT
Clear Street analyst Bill Maughan lowered the price target on WAVE Life Sciences (NASDAQ: WVE) to $39.00 (from $50.00) while maintaining a Buy rating.
The analyst comments "We are updating our model to reflect peak 15% penetration into the Rx-treated US obesity market (20% Europe) (prev. 20% and... More
March 26, 2026 12:23 PM EDT
B.Riley analyst Madison El-Saadi reiterated a Buy rating and $37.00 price target on WAVE Life Sciences (NASDAQ: WVE).
The analyst comments "We reiterate our Buy rating on WVE ($37 PT under review) following this morning's mixed INLIGHT Ph1 6-month (240 mg) and 3-month (400 mg) data that... More
March 26, 2026 9:37 AM EDT
Jefferies analyst Roger Song reiterated a Buy rating and $28.00 price target on WAVE Life Sciences (NASDAQ: WVE).
The analyst comments "Bottom line. We see the update validated INHBE fat-targeting MOA showing durable fat loss from 3mo to 6mo while preserving muscle, resulting in a net weight loss. However, given Ph1 population had lower BMI vs. that from comp... More
